Spartalizumab

DB14892InvestigationalProtein Based Therapies

Spartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).

Mechanism: Pharmacologically active on Programmed cell death protein 1
Curator reviewed
Code names: PDR-001

Resolves to

Compound

UNIIQOG25L6Z8ZCAS1935694-88-4

Targets

Q15116PDCD1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

66Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Spartalizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account